530 related articles for article (PubMed ID: 8864678)
41. The expression of 8-hydroxydeoxyguanosine in oesophageal tissues and tumours.
Räsänen JV; Sihvo EI; Ahotupa MO; Färkkilä MA; Salo JA
Eur J Surg Oncol; 2007 Dec; 33(10):1164-8. PubMed ID: 17467227
[TBL] [Abstract][Full Text] [Related]
42. The molecular biology of esophageal adenocarcinoma.
Koppert LB; Wijnhoven BP; van Dekken H; Tilanus HW; Dinjens WN
J Surg Oncol; 2005 Dec; 92(3):169-90. PubMed ID: 16299787
[TBL] [Abstract][Full Text] [Related]
43. Non-biopsy detection of intestinal metaplasia and dysplasia in Barrett's esophagus: a prospective multicenter study.
Sharma P; Marcon N; Wani S; Bansal A; Mathur S; Sampliner R; Lightdale C
Endoscopy; 2006 Dec; 38(12):1206-12. PubMed ID: 17163320
[TBL] [Abstract][Full Text] [Related]
44. A surveillance programme for Barrett's oesophagus in a UK general hospital.
Olithselvan A; Gorard DA; McIntyre AS
Eur J Gastroenterol Hepatol; 2007 Apr; 19(4):305-9. PubMed ID: 17353694
[TBL] [Abstract][Full Text] [Related]
45. Management of Barrett's esophagus free of dysplasia.
DeMeester SR
Semin Thorac Cardiovasc Surg; 1997 Jul; 9(3):279-84. PubMed ID: 9263346
[TBL] [Abstract][Full Text] [Related]
46. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma.
González MV; Artímez ML; Rodrigo L; López-Larrea C; Menéndez MJ; Alvarez V; Pérez R; Fresno MF; Pérez MJ; Sampedro A; Coto E
J Clin Pathol; 1997 Mar; 50(3):212-7. PubMed ID: 9155671
[TBL] [Abstract][Full Text] [Related]
47. Barrett's esophagus: a retrospective analysis of 13 years surveillance.
Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M
J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769
[TBL] [Abstract][Full Text] [Related]
48. A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus.
Brabender J; Marjoram P; Salonga D; Metzger R; Schneider PM; Park JM; Schneider S; Hölscher AH; Yin J; Meltzer SJ; Danenberg KD; Danenberg PV; Lord RV
Oncogene; 2004 Jun; 23(27):4780-8. PubMed ID: 15107828
[TBL] [Abstract][Full Text] [Related]
49. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
[TBL] [Abstract][Full Text] [Related]
50. MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma.
Wijnhoven BP; Hussey DJ; Watson DI; Tsykin A; Smith CM; Michael MZ;
Br J Surg; 2010 Jun; 97(6):853-61. PubMed ID: 20301167
[TBL] [Abstract][Full Text] [Related]
51. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report.
Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A
Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596
[TBL] [Abstract][Full Text] [Related]
52. p53 and ras gene expression in human esophageal cancer and Barrett's epithelium: a prospective study.
Sorsdahl K; Casson AG; Troster M; Van Meyel D; Inculet R; Chambers AF
Cancer Detect Prev; 1994; 18(3):179-85. PubMed ID: 8076380
[TBL] [Abstract][Full Text] [Related]
53. Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
Griffiths EA; Pritchard SA; McGrath SM; Valentine HR; Price PM; Welch IM; West CM
Br J Cancer; 2007 May; 96(9):1377-83. PubMed ID: 17437013
[TBL] [Abstract][Full Text] [Related]
54. Prognostic value of p53 in Barrett's oesophagus.
Krishnadath KK; van Blankenstein M; Tilanus HW
Eur J Gastroenterol Hepatol; 1995 Jan; 7(1):81-4. PubMed ID: 7866817
[TBL] [Abstract][Full Text] [Related]
55. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.
Hruban RH; van Mansfeld AD; Offerhaus GJ; van Weering DH; Allison DC; Goodman SN; Kensler TW; Bose KK; Cameron JL; Bos JL
Am J Pathol; 1993 Aug; 143(2):545-54. PubMed ID: 8342602
[TBL] [Abstract][Full Text] [Related]
56. Prostaglandin EP2 receptor expression is increased in Barrett's oesophagus and oesophageal adenocarcinoma.
Jiménez P; Piazuelo E; Cebrian C; Ortego J; Strunk M; García-Gonzalez MA; Santander S; Alcedo J; Lanas A
Aliment Pharmacol Ther; 2010 Feb; 31(3):440-51. PubMed ID: 19843025
[TBL] [Abstract][Full Text] [Related]
57. Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus.
Leedham SJ; Preston SL; McDonald SA; Elia G; Bhandari P; Poller D; Harrison R; Novelli MR; Jankowski JA; Wright NA
Gut; 2008 Aug; 57(8):1041-8. PubMed ID: 18305067
[TBL] [Abstract][Full Text] [Related]
58. Lymphatic vessel density in the neoplastic progression of Barrett's oesophagus to adenocarcinoma.
Brundler MA; Harrison JA; de Saussure B; de Perrot M; Pepper MS
J Clin Pathol; 2006 Feb; 59(2):191-5. PubMed ID: 16443737
[TBL] [Abstract][Full Text] [Related]
59. Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence.
Walch AK; Zitzelsberger HF; Bruch J; Keller G; Angermeier D; Aubele MM; Mueller J; Stein H; Braselmann H; Siewert JR; Höfler H; Werner M
Am J Pathol; 2000 Feb; 156(2):555-66. PubMed ID: 10666385
[TBL] [Abstract][Full Text] [Related]
60. Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma.
Brankley SM; Fritcher EG; Smyrk TC; Keeney ME; Campion MB; Voss JS; Clayton AC; Wang KK; Lutzke LS; Kipp BR; Halling KC
Hum Pathol; 2012 Feb; 43(2):172-9. PubMed ID: 21820152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
